Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab and in-office nasal polypectomy in chronic rhinosinusitis (three-arm)
2023-505426-34-01Phase 4Authorised
- Sponsor
- IDIVAL
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by IDIVAL. Primary endpoint: SINO-NASAL OUTCOME TEST (SNOT-22). Planned start Oct 2023; status: authorised.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2023-505426-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505426-34-01.